↓ Skip to main content

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

Overview of attention for article published in BMC Cardiovascular Disorders, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#31 of 1,019)
  • High Attention Score compared to outputs of the same age (88th percentile)

Mentioned by

news
1 news outlet
twitter
14 tweeters

Citations

dimensions_citation
28 Dimensions

Readers on

mendeley
89 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
Published in
BMC Cardiovascular Disorders, June 2017
DOI 10.1186/s12872-017-0591-5
Pubmed ID
Authors

Julian P. Halcox, José R. Banegas, Carine Roy, Jean Dallongeville, Guy De Backer, Eliseo Guallar, Joep Perk, David Hajage, Karin M. Henriksson, Claudio Borghi

Abstract

Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol. This cross-sectional observational study assessed the prevalence of two atherogenic dyslipidemia markers, high triglyceride levels and low high-density lipoprotein cholesterol levels, in the study population from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA; N = 7641; of whom 51.6% were female and 95.6% were White/Caucasian). The EURIKA population included European patients, aged at least 50 years with at least one cardiovascular risk factor but no history of cardiovascular disease. Over 20% of patients from the EURIKA population have either triglyceride or high-density lipoprotein cholesterol levels characteristic of atherogenic dyslipidemia. Furthermore, the proportions of patients with one of these markers were higher in subpopulations with type 2 diabetes mellitus or those already calculated to be at high risk of cardiovascular disease. Approximately 55% of the EURIKA population who have markers of atherogenic dyslipidemia are not receiving lipid-lowering therapy. A considerable proportion of patients with at least one major cardiovascular risk factor in the primary cardiovascular disease prevention setting have markers of atherogenic dyslipidemia. The majority of these patients are not receiving optimal treatment, as specified in international guidelines, and thus their risk of developing cardiovascular disease is possibly underestimated. The present study is registered with ClinicalTrials.gov (ID: NCT00882336).

Twitter Demographics

The data shown below were collected from the profiles of 14 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Unknown 88 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 13%
Student > Master 11 12%
Student > Doctoral Student 9 10%
Researcher 9 10%
Other 8 9%
Other 24 27%
Unknown 16 18%
Readers by discipline Count As %
Medicine and Dentistry 34 38%
Nursing and Health Professions 8 9%
Biochemistry, Genetics and Molecular Biology 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Neuroscience 3 3%
Other 10 11%
Unknown 24 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 April 2020.
All research outputs
#1,050,043
of 15,474,295 outputs
Outputs from BMC Cardiovascular Disorders
#31
of 1,019 outputs
Outputs of similar age
#29,824
of 269,111 outputs
Outputs of similar age from BMC Cardiovascular Disorders
#1
of 1 outputs
Altmetric has tracked 15,474,295 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,019 research outputs from this source. They receive a mean Attention Score of 3.6. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,111 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them